Which drugs are effective for weight loss in adults with type 2 diabetes?
From: The Cochrane Collaboration
- Norris, S.L., Zhang, X., Avenell, A., Gregg, E., Schmid, C.H., Lau, J., 2005. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus, in: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.
- 22 trials with 3,379 participants
- The paper is a systematic review / meta analysis of all relevant trials.
- This means that the data from all similar trials has been grouped together to form an overall outcome.
- Fluoxetine produced an average weight loss of 5.1 kg at 24 - 26 weeks; orlistat 2.0 kg at 12 - 57 weeks, and sibutramine 5.1 kg at 12 - 52 weeks.
- Gastrointestinal side effects were common with orlistat; tremor, somnolence and sweating with fluoxetine; and palpitations with sibutramine.
- A number of weaker trials highlighted a significant decrease in weight with mazindol, phenmetrazine, and phentermine.
- No suitable studies were identified for pseudoephedrine, ephedra, sertraline, yohimbine, amphetamine or its derivatives, bupropion, topiramate, benzocaine, threachlorocitric acid, sertraline, and bromocriptine.
- The authors conclude that fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 12 to 57 weeks. However, the amount of weight loss is modest and the long-term health benefits remain unclear. The safety of sibutramine is uncertain.
- Yes (with confidence) – for fluoxetine, orlistat, and sibutramine